Mercer Global Advisors
ADPT icon

Mercer Global Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Mercer Global Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,034
Closed -$593K – 1625
2020
Q4 		$593K Sell
10,034
-4,977
-33% -$257K 0.01% 798
2020
Q3 		$730K Sell
15,011
-3
-0% -$126 0.01% 651
2020
Q2 		$726K Buy
15,014
+2
+0% +$73 0.01% 563
2020
Q1 		$417K Buy
+15,012
New +$419K 0.01% 707

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Mercer Global Advisors's ADPT Position: Q1 2021 in Review

Mercer Global Advisors sold out of Adaptive Biotechnologies (ADPT) in Q1 2021, closing a stake of 10,034 shares — an estimated $593K sold.

Mercer Global Advisors first reported a position in ADPT in Q1 2020 and held it in 4 quarters. The position peaked at $730K in Q3 2020. 248 funds tracked by Wall St. Rank hold ADPT as of Q1 2021.

  • Mercer Global Advisors reported no remaining Adaptive Biotechnologies position as of Q1 2021 after selling out during the quarter.
  • Mercer Global Advisors sold 10,034 Adaptive Biotechnologies shares in Q1 2021, an estimated $593K.
  • Mercer Global Advisors first reported a position in Adaptive Biotechnologies in Q1 2020 and held it in 4 quarters.
  • Mercer Global Advisors's Adaptive Biotechnologies position peaked at $730K in Q3 2020.
  • 248 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2021.

Based on Mercer Global Advisors's 13F filing for Q1 2021, filed 11 May 2021.